Special drug use-results survey on ERLEADA 60 mg Tablets (Long-term use in patients with non-distant metastatic castration-resistant prostate cancer)

Special drug use-results survey on ERLEADA 60 mg Tablets (Long-term use in patients with non-distant metastatic castration-resistant prostate cancer) - ELD1L

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036808

Enrollment

200

Registered

2019-05-31

Start date

2019-05-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-distant metastatic castration-resistant prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients with non-distant metastatic castration-resistant prostate cancer who received ERLEADA for the first time are targeted. The target patients must understand the contents of this survey and give consent to participation.

Exclusion criteria

Exclusion criteria: Patients with a history of the use of Apalutamide

Design outcomes

Primary

Measure	Time frame
[Patient composition] (a)Number of patients registered (b)Number of patients whose CRFs were collected (c)Number of patients for safety analysis (d) Number of patients excluded for analysis and the reason for exclusion [Safety analysis] (a) Incidence of safety specifications (b) Factors considered affecting safety specification (incidence by patient background, etc.)	—

Countries

Japan

Contacts

Public ContactSayuri Harada

Janssen Pharmaceutical K.K. Safety Risk Management Dept.

sharada8@its.jnj.com03-4411-5874

Outcome results